论文部分内容阅读
严重急性呼吸综合征(SARS)尚无有效治疗方法,一般用经验性抗病毒疗法,静注或口服利巴韦林,皮质甾类与静注免疫球蛋白。体外试验中已证实干扰素可抑制SARS病毒,与γ-干扰素相比,Intreferon alfaeon-1(Alfocon-1 IFN)抗病毒活性最高。alfacon-1 IFN是一种合成的α-IFN,在细胞培养系统与比较研究中,其抑制病毒复制能力大于其他1型IFN。本研究旨在评估alfacon—1 IFN治疗SARS的有益作用与安全性。
There is no effective treatment for severe acute respiratory syndrome (SARS), usually with empirical antiviral therapy, intravenous or oral ribavirin, corticosteroids and intravenous immunoglobulin. It has been demonstrated in vitro that interferon inhibits the SARS virus and that Intreferon alfaeon-1 (Alfocon-1 IFN) has the highest antiviral activity compared to interferon-gamma. alfacon-1 IFN is a synthetic α-IFN that inhibits viral replication more than other type 1 IFNs in cell culture systems and in comparative studies. This study was designed to evaluate the beneficial effects and safety of alfacon-1 IFN in the treatment of SARS.